NEW YORK (GenomeWeb News) – Epigenomics today said that it has established a Level 1 American Depositary Receipt program enabling the firm to trade publicly in the US.

The Berlin, Germany-based molecular diagnostics firm said that its ADRs are US dollar-negotiable certificates that represent ordinary shares of the company at a ratio of five ordinary shares to one Epigenomics ADR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.